Surveillance of Measles-Mumps-Rubella Vaccine-Associated Aseptic Meningitis in Germany

Institutional Login
Logged in as:
dr FIRMAN ABDULLAH (239-67-736)
Log Out
My Menu
Marked Items
Alerts
Order History
Saved Items
All
Favorites Content Types
All Publications Journals Book Series Books Reference Works Protocols Subject Collections
Architecture and Design Behavioral Science Biomedical and Life Sciences Business and Economics Chemistry and Materials Science Computer Science Earth and Environmental Science Engineering Humanities, Social Sciences and Law Mathematics and Statistics Medicine Physics and Astronomy Professional and Applied Computing 中文(简体) 中文(繁體) English Deutsch 한국어 日本語 Français Español العربية Русский Back to: All Content Items Previous Result Next Result
Journal Article

Surveillance of Measles-Mumps-Rubella Vaccine-Associated Aseptic Meningitis in Germany
Journal Infection
Publisher Urban & Vogel
ISSN 0300-8126 (Print) 1439-0973 (Online)
Issue Volume 30, Number 6 / December, 2002
Category Clinical and Epidemiological Study
DOI 10.1007/s15010-002-3027-8
Pages 351-355
Subject Collection Medicine
SpringerLink Date Sunday, December 01, 2002
Add to marked items
Add to shopping cart
Add to saved items
Permissions & Reprints
Recommend this article


Disable Highlighting PDF (93.4 KB)Free Preview

Clinical and Epidemiological Study
Surveillance of Measles-Mumps-Rubella Vaccine-Associated Aseptic Meningitis in Germany
U. Schlipköter1, N. Mühlberger2, R. von Kries3 and J. Weil4

(1) Institute for Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilian University, Marchioninistr. 15, D-81377 Munich, Germany. schli@ibe.med.uni-muenchen.de, DE
(2) Dept. of Infectiology and Tropical Medicine, SIMPID Coordination Center, LMU, Leopoldstr. 5, D-80802 München, Germany. muehlberger@lrz.uni-muenchen.de, DE
(3) Institute for Social Pediatrics, Ludwig-Maximilian University, Munich, Germany. ruediger.kries@t-online.de, DE
(4) GlaxoSmithCline Biologicals, Rue de l'Institut 89B, B-1330 Rixensart Belgium. john.g.weil@gsk.com, BE

Abstract.
Background: The study objective was to detect any incidence of aseptic meningitis associated with measles-mumps-rubella (MMR) vaccines that would be considered of public health importance subsequent to the introduction of a new MMR vaccine (Priorix™).
Patients and Methods: Adverse drug reaction (ADR) rates were calculated by relating the number of cases to the number of doses of the different MMR vaccines distributed during a 2-year period in Germany.
Results: During the 2-year study period 1,575,936 doses of Priorix™ and 1,907,875 doses of other MMR vaccines were distributed in Germany. There were no confirmed cases of aseptic meningitis associated with MMR vaccination during this period. Thus, the ADR rates (rejectable with 5% alpha error) were lower than 1/525,312 for Priorix™ and lower than 1/635,958 for other MMR vaccines.
Conclusion: The safety profile of the Priorix™ is similar to that of other MMR vaccines used in Germany.
Received: February 7, 2002 · Revision accepted: July 9, 2002
U. Schlipköter (corresponding author)

--------------------------------------------------------------------------------

Fulltext Preview (Small, Large)
more options Find Query Builder Close | Clear Title (ti) Summary (su) Author (au) ISSN (issn) ISBN (isbn) DOI (doi) And Or Not ( ) * (wildcard) "" (exact) Within all content
Within this journal
Within this issue
Export this article Export this article as RIS | Text

Referenced by 1 newer article


Peltola, Heikki (2007) Mumps Outbreaks in Canada and the United States: Time for New Thinking on Mumps Vaccines. Clinical Infectious Diseases 45(4)
[CrossRef]


Frequently asked questions | General information on journals and books | Send us your feedback | Impressum | Contact
© Springer. Part of Springer Science+Business Media
Privacy, Disclaimer, Terms and Conditions, © Copyright Information
Privacy Policy
Remote Address: 125.162.59.27 • Server: MPWEB25
HTTP User Agent: Mozilla/4.0 (compatible; MSIE 7.0; Windows NT 5.1; GTB5; 3P_UVRM 1.0.23.0)